The second-generation leukemia drug, 'Bosulif,' has landed in 'Big 5' general hospitals.

According to industry sources, Pfizer Korea's chronic myelogenous leukemia (CML) drug, Bosulif, has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, and Sinchon Severance Hospital. It is now available for prescription at 21 nationwide medical centers.

After making the insurance reimbursement list in January, it has quickly become available for prescription.

However, some patients are expressing disappointment regarding the reimbursement criteria. Bosulif's reimbursement crite